Clinical EfficacySION-719 and SION-451 have shown highly compelling data in a validated preclinical assay, coupled with safety data suggesting they can achieve high exposures in patients for clinical efficacy.
Financial PositionSION ended 1Q25 with $354.7M cash, including net proceeds of $199.6M from the recent successful IPO, providing operating expense runway into 2028.
Pipeline DevelopmentSION's NBD1 Pipeline Represents The First Candidates In This Class To Successfully Enter clinical trials.